News >

Olaparib Improves Radiographic PFS in HRR-Mutant mCRPC

Gina Columbus @ginacolumbusonc
Published: Wednesday, Aug 07, 2019

Jose Baselga, MD

José Baselga, MD

Olaparib (Lynparza) demonstrated a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared with enzalutamide (Xtandi) or abiraterone acetate (Zytiga) in patients with metastatic castration-resistant prostate cancer (mCRPC) who harbor a homologous recombination repair (HRR) gene mutation and have progressed on prior therapy with either androgen receptor (AR) inhibitor, meeting the primary endpoint of the phase III PROfound trial (NCT02987543).1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x